ClinicalTrials.gg
CompletedNCT00300677Updated Oct 14, 2009Results posted

To Determine The Amount Of Voriconazole In The Brain After 2 Loading Doses And 3 Maintenance Doses Over 3 Days

A Phase 4 interventional study of voriconazole in Infections, Fungal, sponsored by Pfizer. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2009-10-14.

Sponsored by Pfizer · Phase 4, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing voriconazole in Mycoses — none open to participants now, none under way, none of them phase 3. Voriconazole · Mycoses.

Enrollment
15th of 17
12 · median 29
Started
2007
the only one that year
Phase 4
4 of 17
none open now
Registered
7th of 17
by date
Lead sponsor
3 of 17
Pfizer

Among the 17 studies testing voriconazole in Mycoses, this one is the 15th largest by enrollment, is the only one that started in 2007, is one of 4 in phase 4, and was the 7th registered.

Mycoses

260 studies on the registry are indexed under Mycoses; 37 are open to participants now.

Browse Mycoses studies →

Open to participants now

None of the 17 studies testing voriconazole in Mycoses is open now. The open studies under Mycoses, anywhere →

About voriconazole

Voriconazole: first FDA approval 2002 (VFEND), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 24 Mycoses studies recruiting now, 13 (54%) set no upper age limit and 4 (17%) stop at 75 or younger; 5 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies testing voriconazole in Mycoses as a file.
02

Study summary

To determine the amount of voriconazole in the brain after 2 loading doses and 3 maintenance doses over 3 days and compare it to the amount of voriconazole in the plasma.

03

Conditions studied

  • Infections, Fungal

Browse trials for

Keywords

  • Pharmacokinetics
  • Voriconazole
  • Magnetic Resonance Spectroscopy
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must be willing and able to provide .
  • Subjects must be willing and able to be confined at the Clinical Research Unit as required by the protocol.

Exclusion criteria

Exclusion Criteria:

  • Subjects with any condition affecting drug absorption.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    voriconazole

    voriconazole twice daily

    Drug: voriconazole

Interventions

  • Multiple oral doses of voriconazole at 400 mg loading twice daily followed by 200 mg maintenance twice daily

    Also known as: Vfend

06

What researchers measure

Primary outcomes

  1. Plasma Concentrations of Voriconazole

    Mean plasma voriconazole concentrations (nanograms per milliliter \[ng/mL\]) pre-dose (Cmin) and two hours post-dose (C2h). Plasma samples were assayed using a validated, sensitive, and specific high performance liquid chromatography/tandem mass spectrometry (HPLC-MS/MS) method.

    Time frame: Day 3: pre-dose, 2 hours post-dose

  2. Brain Concentrations of Voriconazole

    Mean brain concentrations (ng/mL) of voriconazole pre-dose and 2 hours post-dose measured by Fluorine (F) Magnetic Resonance Spectroscopy (F-MRS).

    Time frame: Day 3: pre-dose, 2 hours post-dose

  3. Plasma Concentrations of N-oxide Metabolite

    Mean plasma concentrations of voriconazole N-oxide metabolite (ng/mL) pre-dose and 2 hours post-dose. Plasma samples were assayed using a validated, sensitive, and specific high performance liquid chromatography/tandem mass spectrometry (HPLC-MS/MS) method.

    Time frame: Day 3: pre-dose, 2 hours post-dose

  4. Brain Concentrations of N-oxide Metabolite

    Mean brain concentrations (ng/mL) of voriconazole N-oxide metabolite pre-dose and 2 hours post-dose measured by Fluorine (F) Magnetic Resonance Spectroscopy (F-MRS).

    Time frame: Day 3: pre-dose, 2 hours post-dose

07

Results

Posted Oct 14, 2009

Participant flow

Healthy male volunteers were recruited by 1 hospital center in the U.S. between March 2007 and August 2008.

Participant flow — Overall Study
MilestoneVoriconazole
Started12
Completed12
Not completed0

Outcome measures

PrimaryPlasma Concentrations of Voriconazole

Mean plasma voriconazole concentrations (nanograms per milliliter \[ng/mL\]) pre-dose (Cmin) and two hours post-dose (C2h). Plasma samples were assayed using a validated, sensitive, and specific high performance liquid chromatography/tandem mass spectrometry (HPLC-MS/MS) method.

Time frame:
Day 3: pre-dose, 2 hours post-dose
Reported as:
Mean · ng/mL
Plasma Concentrations of Voriconazole
ng/mLVoriconazole
predose (Cmin)839.50 ± 874.22
2 hours postdose (C2h)2182.33 ± 1190.63
Statistical analysis
  • Voriconazole · ANOVA · Predose: ratio adjusted geometric means: 300.28 · 90% CI 192.91 to 467.43Estimated value = ratio (%) of adjusted geometric means comparing brain (test) vs. plasma (reference) concentrations of voriconazole.
  • Voriconazole · ANOVA · Postdose: ratio adjusted geometric means: 192.72 · 90% CI 123.81 to 300.00Estimated value = ratio (%) of adjusted geometric means comparing brain (test) vs. plasma (reference) concentrations of voriconazole.
PrimaryBrain Concentrations of Voriconazole

Mean brain concentrations (ng/mL) of voriconazole pre-dose and 2 hours post-dose measured by Fluorine (F) Magnetic Resonance Spectroscopy (F-MRS).

Time frame:
Day 3: pre-dose, 2 hours post-dose
Reported as:
Mean · ng/mL
Brain Concentrations of Voriconazole
ng/mLVoriconazole
predose (Cmin)2090.44 ± 1227.88
2 hours postdose (C2h)4165.20 ± 1806.93
Statistical analysis
  • Voriconazole · ANOVA · Predose: ratio adjusted geometric means: 300.28 · 90% CI 192.91 to 467.43Estimated value = ratio (%) of the adjusted geometric means comparing brain (test) vs. plasma (reference) concentrations of voriconazole.
  • Voriconazole · ANOVA · Postdose: ratio adjusted geometric means: 192.72 · 90% CI 123.81 to 300.00Estimated value = ratio (%) of adjusted geometric means comparing brain (test) vs. plasma (reference) concentrations of voriconazole.
PrimaryPlasma Concentrations of N-oxide Metabolite

Mean plasma concentrations of voriconazole N-oxide metabolite (ng/mL) pre-dose and 2 hours post-dose. Plasma samples were assayed using a validated, sensitive, and specific high performance liquid chromatography/tandem mass spectrometry (HPLC-MS/MS) method.

Time frame:
Day 3: pre-dose, 2 hours post-dose
Reported as:
Mean · ng/mL
Plasma Concentrations of N-oxide Metabolite
ng/mLVoriconazole
predose (Cmin)3076.67 ± 841.96
2 hours postdose (C2h)3665.00 ± 958.73
Statistical analysis
  • Voriconazole · ANOVA · Predose: ratio adjusted geometric means: 12.39 · 90% CI 7.09 to 21.65Estimated value = ratio (%) of adjusted geometric means comparing brain (test) vs. plasma (reference) concentrations of voriconazole N-oxide.
  • Voriconazole · ANOVA · Postdose: ratio adjusted geometric means: 31.57 · 90% CI 18.06 to 55.18Estimated value = ratio (%) of adjusted geometric means comparing brain (test) vs. plasma (reference) concentrations of voriconazole N-oxide.
PrimaryBrain Concentrations of N-oxide Metabolite

Mean brain concentrations (ng/mL) of voriconazole N-oxide metabolite pre-dose and 2 hours post-dose measured by Fluorine (F) Magnetic Resonance Spectroscopy (F-MRS).

Time frame:
Day 3: pre-dose, 2 hours post-dose
Reported as:
Mean · ng/mL
Brain Concentrations of N-oxide Metabolite
ng/mLVoriconazole
predose (Cmin)663.97 ± 677.55
2 hours postdose (C2h)1535.40 ± 1280.09
Statistical analysis
  • Voriconazole · ANOVA · Predose: ratio adjusted mean: 12.39 · 90% CI 7.09 to 21.65Estimated value = ratio (%) of adjusted geometric means comparing brain (test) vs. plama (reference) concentrations of voriconazole N-oxide.
  • Voriconazole · ANOVA · Postdose: ratio adjusted mean: 31.57 · 90% CI 18.06 to 55.18Estimated value = ratio (%) of adjusted geometric means comparing brain (test) vs. plasma (reference) concentrations of voriconazole N-oxide.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Voriconazole—0/12 (0%)11/12 (91.7%)
Most frequent other events
Showing 10 of 18
Most frequent other events
EventVoriconazole
PhotophobiaEye disorders5/12
HeadacheNervous system disorders4/12
Vision blurredEye disorders3/12
Dry mouthGastrointestinal disorders2/12
Procedural dizzinessInjury, poisoning and procedural complications2/12
DizzinessNervous system disorders2/12
Head discomfortNervous system disorders2/12
Ear discomfortEar and labyrinth disorders1/12
Dry eyeEye disorders1/12
Abdominal painGastrointestinal disorders1/12

Baseline characteristics

Age, Customized
Age, Customized(participants)Voriconazole
18-25 years3
26-35 years6
36-45 years3
Sex: Female, Male
Sex: Female, Male(Participants)Voriconazole
Female0
Male12
08

Study locations

1 site
  • Pfizer Investigational Site
    Belmont, Massachusetts 02478-1041, United States
09

References and documents

Publications

  • Henry ME, Bolo NR, Zuo CS, Villafuerte RA, Cayetano K, Glue P, Damle BD, Andrews E, Lauriat TL, Rana NS, Churchill JH, Renshaw PF. Quantification of brain voriconazole levels in healthy adults using fluorine magnetic resonance spectroscopy. Antimicrob Agents Chemother. 2013 Nov;57(11):5271-6. doi: 10.1128/AAC.00394-13. Epub 2013 Aug 12. PubMed 23939898 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2007, a primary completion of Aug 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2009, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2006
First posted
Mar 9, 2006
Start
Mar 2007
Primary completionActual
Aug 2008
CompletionActual
Aug 2008
Results first posted
Oct 14, 2009
Last update
Oct 14, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 14, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00300677
Lead sponsor
Pfizer
Collaborators
McLean Hospital. Belmont, MA.
First posted
Mar 9, 2006
Start date
Mar 2007
Primary completion
Aug 2008
Completion
Aug 2008
Results posted
Oct 14, 2009
Last update
Oct 14, 2009

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Voriconazole

Start the discussion